Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Measuring the Influence of Kefir on Children's Stools on Antibiotics (MILK)
This study has been completed.
Sponsors and Collaborators: Georgetown University
Lifeway Foods, Inc.
Information provided by: Georgetown University
ClinicalTrials.gov Identifier: NCT00481507
  Purpose

The purpose of this study is to determine the effectiveness of commercially available kefir on preventing antibiotic-associated diarrhea compared to placebo in children ages 1-5.


Condition Intervention Phase
Respiratory Tract Infections
Drug: Kefir
Phase III

MedlinePlus related topics: Antibiotics Diarrhea
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study
Official Title: Measuring the Influence of Kefir on Children's Stools on Antibiotics (MILK)

Further study details as provided by Georgetown University:

Primary Outcome Measures:
  • decrease parental report of loose stool [ Time Frame: 14 days ]

Secondary Outcome Measures:
  • total bowel movements, number of diapers used, missed school and work days and parental satisfaction and parental assessment of overall global health. [ Time Frame: 14 days ]

Enrollment: 125
Study Start Date: July 2007
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Detailed Description:

Diarrhea is a common and costly disease of children in the United States. Children less than 5 years of age experience 20-35 million episodes of diarrhea per year. These episodes lead to 2-3.5 million physician visits (which account for 10% of all visits), more than 200,000 hospitalizations (13% of hospital admissions in children less than 5 years), and 325-425 deaths annually. In 1991, the outpatient costs of treating diarrhea for children under age 3 were calculated at 0.6-1 billion dollars per year.

Acute diarrhea in young children is almost always caused by infections or antibiotics. The rate of diarrhea associated with antibiotic usage is 20-35%, with children 3-36 months receiving on average 2-3 antibiotic prescriptions per year. Studies have shown that diarrhea due to either antibiotics or infections is caused by disturbances of the microflora of the gastrointestinal tract.

The current treatment for diarrhea in young children is oral rehydration, which is used to treat dehydration but plays no role in prevention. Probiotics are live microorganisms which, when administered in sufficient amounts, may improve health. Probiotics have the potential to treat and prevent diarrhea by improving the intestinal flora when disturbed by events such as antibiotics. Important to their use is that they are of human origin, survive passage through the gut, and are safe in very large dosages.

Studies have examined the potential health benefits of probiotics in the prevention and treatment of both antibiotic and infectious diarrhea. The probiotics have generally been given as supplements or pills. In placebo controlled randomized studies using these techniques, probiotics have generally been shown to decrease antibiotic associated diarrhea by 15-25% over placebo. Other studies have enrolled children with acute diarrhea, generally from rotavirus, and found a 30-50% cure rate in the probiotic group over placebo.

Kefir, available in the United States, is a milk product derived by the action of ten probiotics. A daily dose of 106-109 colony forming units of probiotics has been studied and recommended for health benefits.

  Eligibility

Ages Eligible for Study:   1 Year to 5 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Ability to speak and write English
  • Aged 1-5 years
  • Male or female
  • Diagnosed with an upper respiratory infection and placed on a penicillin class antibiotic regimen for 10 days

Exclusion Criteria:

  • Developmental delays
  • Chronic conditions, such as diabetes or asthma, that require medication
  • Prematurity, birth weight <2500 grams
  • Allergy to kefir and/or milk
  • Active diarrhea
  • Congenital anomalies
  • Failure to thrive
  • Parental belief of lactose intolerance
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00481507

Locations
United States, District of Columbia
Georgetown University Deptartment of Family Medicine
Washington, District of Columbia, United States, 20007
Sponsors and Collaborators
Georgetown University
Lifeway Foods, Inc.
Investigators
Principal Investigator: Daniel Merenstein, MD Georgetown University
  More Information

Responsible Party: Lifeway Foods, Inc. ( Julie Smolyansky )
Study ID Numbers: 2007-146
Study First Received: May 30, 2007
Last Updated: May 12, 2008
ClinicalTrials.gov Identifier: NCT00481507  
Health Authority: United States: Institutional Review Board

Keywords provided by Georgetown University:
Probiotic
Cultured dairy drink
Health
10 day antibiotic
Otherwise healthy

Study placed in the following topic categories:
Respiratory Tract Diseases
Respiratory Tract Infections
Healthy

Additional relevant MeSH terms:
Infection

ClinicalTrials.gov processed this record on January 13, 2009